Begin main content

halobetasol propionate and tazarotene

Last Updated: February 20, 2019
Result type: Reports
Project Number: SR0600-000
Product Line: Common Drug Review

Generic Name: halobetasol propionate and tazarotene

Brand Name: TBC

Manufacturer: Bausch Health, Canada Inc.

Indications: Psoriasis, moderate to severe plaque

Manufacturer Requested Reimbursement Criteria1: Topical treatment of moderate-to-severe plaque psoriasis.

Submission Type: New

Project Status: Withdrawn

Biosimilar: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input posted January 07, 2019
Submission received February 04, 2019
Clarification:

- Voluntarily withdrawn by the manufacturer on 2019-Feb-19

Tags

dermatology